ES2384208T3 - Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. - Google Patents
Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. Download PDFInfo
- Publication number
- ES2384208T3 ES2384208T3 ES06077149T ES06077149T ES2384208T3 ES 2384208 T3 ES2384208 T3 ES 2384208T3 ES 06077149 T ES06077149 T ES 06077149T ES 06077149 T ES06077149 T ES 06077149T ES 2384208 T3 ES2384208 T3 ES 2384208T3
- Authority
- ES
- Spain
- Prior art keywords
- vol
- cancer
- mmc
- bioreductive
- bladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010005003 Bladder cancer Diseases 0.000 title claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002842 anticancer formulation Substances 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 claims description 13
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 8
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 102000004316 Oxidoreductases Human genes 0.000 claims description 5
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000001146 hypoxic effect Effects 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- -1 1-aziridinyl Chemical group 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 238000012552 review Methods 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000035572 chemosensitivity Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000008520 organization Effects 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 238000002271 resection Methods 0.000 claims description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 5
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 3
- 230000000144 pharmacologic effect Effects 0.000 claims 3
- 229960000948 quinine Drugs 0.000 claims 3
- 230000002152 alkylating effect Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 238000009509 drug development Methods 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 2
- 206010051779 Bone marrow toxicity Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 231100000366 bone marrow toxicity Toxicity 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000013115 immunohistochemical detection Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 abstract 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012143 endoscopic resection Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34444601P | 2001-11-01 | 2001-11-01 | |
| US344446P | 2001-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2384208T3 true ES2384208T3 (es) | 2012-07-02 |
Family
ID=23350584
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06077149T Expired - Lifetime ES2384208T3 (es) | 2001-11-01 | 2002-11-01 | Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. |
| ES09075067T Expired - Lifetime ES2341922T3 (es) | 2001-11-01 | 2002-11-01 | Composiciones medicas para el tratamiento intravesical de cancer de vejiga. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09075067T Expired - Lifetime ES2341922T3 (es) | 2001-11-01 | 2002-11-01 | Composiciones medicas para el tratamiento intravesical de cancer de vejiga. |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US6894071B2 (https=) |
| EP (3) | EP1439835A2 (https=) |
| JP (1) | JP4317452B2 (https=) |
| AT (2) | ATE455545T1 (https=) |
| AU (1) | AU2002350115A1 (https=) |
| CA (2) | CA2789114C (https=) |
| CY (1) | CY1111252T1 (https=) |
| DE (2) | DE60235214D1 (https=) |
| DK (2) | DK2060259T3 (https=) |
| ES (2) | ES2384208T3 (https=) |
| PT (2) | PT2060259E (https=) |
| WO (1) | WO2003037314A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002350115A1 (en) | 2001-11-01 | 2003-05-12 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
| US8563592B2 (en) * | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
| US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| AU2006230582A1 (en) * | 2005-03-31 | 2006-10-05 | Spectrum Pharmaceuticals, Inc. | Indoloquinone tumor radiation sensitization |
| WO2006130978A1 (en) | 2005-06-06 | 2006-12-14 | The University Of British Columbia | Polymer-based serum albumin substitute |
| RU2396953C2 (ru) * | 2006-02-09 | 2010-08-20 | Спектрум Фармасьютикалз, Инк. | Лечение рака мочевого пузыря с использованием ео9 и пропиленгликоля |
| WO2008147445A2 (en) * | 2006-11-09 | 2008-12-04 | University Of Maryland, Baltimore | Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent |
| AU2008224962B2 (en) * | 2007-03-13 | 2013-07-25 | Spectrum Pharmaceuticals, Inc. | Intravesical apaziquone administration following transurethral resection for treating cancer |
| RU2354386C1 (ru) * | 2007-12-26 | 2009-05-10 | ГУ Московская городская онкологическая больница №62 Департамента здравоохранения г. Москвы | Способ профилактики рецидивов поверхностного рака мочевого пузыря |
| GB0800311D0 (en) * | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
| WO2011089604A2 (en) | 2010-01-20 | 2011-07-28 | Theracoat Ltd | Material and method for treating internal cavities |
| BR112012021991A2 (pt) | 2010-03-01 | 2020-09-01 | The University Of British Columbia | policlicerol hiperramificado uso de um poliglicerol hipermanificado, método de adiministração de uma força biologicamente ativa a um tecido biológico, composição farmacêutica e método de síntese de um poliglicerol hiperrramificado. |
| WO2012040492A1 (en) * | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Methods of treating cancer comprising targeting nqo1 |
| WO2013011504A1 (en) | 2011-07-20 | 2013-01-24 | Theracoat Ltd. | Materials and method for treating internal body cavities |
| JP6495654B2 (ja) | 2011-10-24 | 2019-04-03 | アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー | シクロヘキシルアミン類 |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| CA2933811C (en) | 2013-12-16 | 2021-02-09 | Asana Biosciences, Llc | P2x3 and/or p2x2/3 compounds and methods |
| CN104743887B (zh) * | 2014-09-22 | 2016-03-23 | 巨石集团有限公司 | 一种玻璃纤维组合物及其玻璃纤维和复合材料 |
| RU2019112740A (ru) | 2016-09-30 | 2020-11-02 | АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи | P2x3 и/или p2x2/3 соединения и способы |
| EP3924521A4 (en) | 2019-02-15 | 2023-03-29 | IncellDx, Inc. | BLADDER-ASSOCIATED SAMPLES TESTING, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREON |
| CN112220742A (zh) * | 2019-07-15 | 2021-01-15 | 深圳艾欣达伟医药科技有限公司 | 稳定的ast-3424注射液制剂及制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| JPS54151134A (en) | 1978-05-19 | 1979-11-28 | Kureha Chem Ind Co Ltd | Antitumorigenic agent |
| NL8001280A (nl) * | 1980-03-04 | 1981-10-01 | Philips Nv | Lagedrukontladingslamp. |
| EP0163696B1 (en) | 1983-11-14 | 1992-11-25 | Columbia Laboratories, Inc. | Use of a bioadhesive |
| US4898729A (en) | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| US4671954A (en) * | 1983-12-13 | 1987-06-09 | University Of Florida | Microspheres for incorporation of therapeutic substances and methods of preparation thereof |
| JPS60163621A (ja) | 1984-02-02 | 1985-08-26 | 村上 俊文 | 紙製便座カバ−の製造方法 |
| JPS60163821A (ja) | 1984-02-03 | 1985-08-26 | Tdk Corp | フエライト粒子を含む薬剤用担体 |
| JPS61189215A (ja) | 1985-02-18 | 1986-08-22 | Teijin Ltd | ５−フルオロ−２′−デオキシウリジンエステル類の油状医薬組成物 |
| EP0302874B1 (en) * | 1986-04-17 | 1992-12-02 | SPECKAMP, Willem Nico | Indoloquinone compounds |
| US4871542A (en) * | 1987-04-30 | 1989-10-03 | Ferring Service Center, N.V. | Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract |
| EP0331635A3 (en) | 1988-02-29 | 1990-02-28 | The Board of Regents of the University of Texas System | Preparations for treating bladder cancer |
| EP0338679A3 (en) | 1988-03-24 | 1991-03-06 | Genentech, Inc. | Tumour necrosis factor in the treatment of bladder cancer |
| FR2629584B1 (fr) | 1988-03-31 | 1993-06-04 | France Etat Armement | Dispositif de stabilisation pour un projectile a faible moment d'inertie longitudinal tire a partir d'un tube raye |
| US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| PT93772A (pt) | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
| US5216011A (en) * | 1989-09-01 | 1993-06-01 | Bristol-Myers Squibb Co. | Stable solutions of mitomycin c |
| FI84874C (fi) | 1989-11-02 | 1992-02-10 | Valio Meijerien | Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den. |
| US5237466A (en) | 1989-11-02 | 1993-08-17 | International Business Machines Corporation | Method and apparatus for programmably controlling spindle synchronization and phase among disk drives in a storage subsystem |
| US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
| US5346703A (en) * | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US5550110A (en) | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| JP3598049B2 (ja) | 1992-09-18 | 2004-12-08 | 山之内製薬株式会社 | ハイドロゲル徐放性製剤 |
| US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| EP0642797B1 (en) | 1993-09-09 | 2000-05-17 | Takeda Chemical Industries, Ltd. | Formulation comprising antibacterial substance and antiulcer substance |
| CA2135151A1 (en) | 1993-11-08 | 1995-05-09 | Mitsuhiro Wakimasu | Cyclic hexapeptides, their production and use |
| US5405622A (en) * | 1993-12-22 | 1995-04-11 | Vernice; Joseph | Gamma radiation resistant lubricating gel |
| TW438601B (en) * | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
| US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| WO1996019233A2 (en) | 1994-12-12 | 1996-06-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5749845A (en) * | 1995-01-25 | 1998-05-12 | Iotek, Inc. | Delivering an agent to an organ |
| WO1997023456A1 (en) | 1995-12-21 | 1997-07-03 | British Technology Group Ltd. | Indoloquinone derivatives as bioreductive agents |
| US5985312A (en) | 1996-01-26 | 1999-11-16 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| JP2000509014A (ja) * | 1996-03-11 | 2000-07-18 | フォーカル，インコーポレイテッド | 放射性核種および放射性医薬品のポリマー送達 |
| US5955096A (en) * | 1996-06-25 | 1999-09-21 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients |
| US6251861B1 (en) | 1996-06-27 | 2001-06-26 | Takeda Chemical Industries, Ltd. | Treatment of cerebral infarction using cyclic hexapeptides |
| JP2967734B2 (ja) * | 1996-10-18 | 1999-10-25 | 日本電気株式会社 | 薄膜の形成方法 |
| KR20010006027A (ko) * | 1997-04-03 | 2001-01-15 | 포인트 바이오메디칼 코퍼레이션 | 방광내 약물 송달 시스템 |
| US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
| AU9082698A (en) * | 1997-09-08 | 1999-03-29 | Theramark Limited | Treatment of inflammatory conditions |
| US6156744A (en) | 1998-03-19 | 2000-12-05 | Cancer Research Campaign Tech (London) | DT-diaphorase directed anti-tumor agents |
| CA2268640A1 (en) | 1998-04-14 | 1999-10-14 | Mitsuru Shiraishi | Composition for preventing or treating ischemic disease |
| US6171610B1 (en) * | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
| WO1999065483A1 (en) | 1998-05-05 | 1999-12-23 | Astrazeneca Ab | Mycobacterial inhibitors |
| IL124957A0 (en) | 1998-06-16 | 1999-01-26 | Univ Ben Gurion | Active ingredient delivery systems and devices based on porous matrices |
| US6087396A (en) * | 1998-10-05 | 2000-07-11 | Situs Corporation | Oxybutynin formulations and method of use |
| GB9827034D0 (en) | 1998-12-10 | 1999-02-03 | Univ Manchester | Delivery formulation |
| JP2000256182A (ja) | 1999-03-03 | 2000-09-19 | Kazuhiro Morimoto | 抗菌製剤 |
| EP1177439B1 (en) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening for immunostimulatory dna functional modifiers |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| JP2003535061A (ja) | 2000-05-31 | 2003-11-25 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | エンドセリン受容体拮抗剤および疼痛軽減特性を有する抗癲癇化合物または鎮痛剤の複合物 |
| JP4323802B2 (ja) | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
| WO2002049630A2 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| WO2003009805A2 (en) | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
| AU2002350115A1 (en) | 2001-11-01 | 2003-05-12 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| WO2003092731A1 (en) | 2002-05-03 | 2003-11-13 | Novo Nordisk A/S | Stabilised solid compositions of modified factor vii |
| US20040009918A1 (en) | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
| CA2502848C (en) | 2002-10-24 | 2012-10-02 | The Board Of Trustees Of The University Of Illinois | Use of irl-1620 and paclitaxel for preventing and treating breast tumors |
| RU2423381C2 (ru) | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| RU2396953C2 (ru) | 2006-02-09 | 2010-08-20 | Спектрум Фармасьютикалз, Инк. | Лечение рака мочевого пузыря с использованием ео9 и пропиленгликоля |
-
2002
- 2002-11-01 AU AU2002350115A patent/AU2002350115A1/en not_active Abandoned
- 2002-11-01 CA CA2789114A patent/CA2789114C/en not_active Expired - Fee Related
- 2002-11-01 JP JP2003539658A patent/JP4317452B2/ja not_active Expired - Lifetime
- 2002-11-01 PT PT09075067T patent/PT2060259E/pt unknown
- 2002-11-01 EP EP02786643A patent/EP1439835A2/en not_active Withdrawn
- 2002-11-01 DK DK09075067.0T patent/DK2060259T3/da active
- 2002-11-01 AT AT09075067T patent/ATE455545T1/de active
- 2002-11-01 ES ES06077149T patent/ES2384208T3/es not_active Expired - Lifetime
- 2002-11-01 PT PT06077149T patent/PT1864660E/pt unknown
- 2002-11-01 ES ES09075067T patent/ES2341922T3/es not_active Expired - Lifetime
- 2002-11-01 DK DK06077149.0T patent/DK1864660T3/da active
- 2002-11-01 DE DE60235214T patent/DE60235214D1/de not_active Expired - Lifetime
- 2002-11-01 CA CA2466148A patent/CA2466148C/en not_active Expired - Fee Related
- 2002-11-01 WO PCT/US2002/035191 patent/WO2003037314A2/en not_active Ceased
- 2002-11-01 US US10/285,783 patent/US6894071B2/en not_active Expired - Lifetime
- 2002-11-01 EP EP09075067A patent/EP2060259B1/en not_active Expired - Lifetime
- 2002-11-01 DE DE60238798T patent/DE60238798D1/de not_active Expired - Lifetime
- 2002-11-01 AT AT06077149T patent/ATE493126T1/de active
- 2002-11-01 EP EP06077149A patent/EP1864660B1/en not_active Expired - Lifetime
-
2005
- 2005-04-01 US US11/096,566 patent/US20050215615A1/en not_active Abandoned
-
2006
- 2006-09-13 US US11/531,535 patent/US20070010570A1/en not_active Abandoned
-
2008
- 2008-03-21 US US12/053,418 patent/US7977369B2/en not_active Expired - Fee Related
- 2008-12-03 US US12/327,781 patent/US20090076123A1/en not_active Abandoned
-
2011
- 2011-02-14 CY CY20111100183T patent/CY1111252T1/el unknown
-
2012
- 2012-06-11 US US13/493,911 patent/US8648108B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2384208T3 (es) | Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. | |
| ES2305134T3 (es) | Utilizacion de cci-779 como un agente antineoplasico. | |
| Shmeeda et al. | Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells | |
| US9872834B2 (en) | Nanocarrier therapy for treating invasive tumors | |
| Thangavel et al. | Redox nanoparticle increases the chemotherapeutic efficiency of pioglitazone and suppresses its toxic side effects | |
| US20040009957A1 (en) | Protective effects of PDE-5 inhibitors | |
| Steinberg et al. | Intravesical valrubicin in the treatment of carcinoma in situ of the bladder | |
| HK1109875A1 (en) | Medical compositions for intravesical treatment of bladder cancer | |
| HK1109875B (en) | Medical compositions for intravesical treatment of bladder cancer | |
| JP2010539135A (ja) | 癌を治療するためのリポソーム製剤 | |
| Uleri et al. | Novel intravesical delivery systems for nonmuscle invasive bladder cancer | |
| US12502383B2 (en) | Pharmaceutical composition of cyclooxygenase-2 inhibitors | |
| EP1653948B1 (en) | Use of 5-methoxytryptamine as a cardioprotective agent | |
| Richard et al. | Delivery of ROS Generating Anthraquinones Using Reduction‐Responsive Peptide‐Based Nanoparticles | |
| HK1132181B (en) | Medical compositions for intravesical treatment of bladder cancer | |
| Bansal | Pharmacokinetic and Biodistribution Analysis of 5-Fluorouracil-and Celecoxib-loaded Eudragit S100-coated Chitosan Microspheres Intended for Colon-specific Delivery | |
| JP2004529893A (ja) | 改善されたバイオアベイラビリティーを有する組成物 | |
| Kulkarni et al. | Supramolecular nanoparticles that target phosphatidylinositol-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy | |
| Martins et al. | Poloxamers-Based Nanomicelles as Delivery Vehicles of Photosensitizers for Hepatic Photodynamic Therapy |